Roche HoldingsCH0012032048ROGROG
Financials
Market Cap
$197.29B5Y beta
0.71EPS (TTM)
$15.62Free Float
719.54MP/E ratio (TTM)
15.43Revenue (TTM)
$64.12BEBITDA (TTM)
$24.03BFree Cashflow (TTM)
-$2.95BPricing
Analyst Ratings
The price target is $299.14 and the stock is covered by 22 analysts.
Buy
9
Hold
8
Sell
5
Information
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.